Vir Biotechnology

VIR BIOTECHNOLOGY INC

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

cancer

Analyst Color

Biotech

Equities

News

Upgrades

Health Care

Price Target

Analyst Ratings

Trading Ideas

General

Vir Biotechnology&#39;s Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here&#39;s Why

Movers

Vir Biotechnology&#39;s Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here&#39;s Why

AAR Corp.

Intraday Update

Markets

ABSI

ADTN

ALTM

ANGO

CALM

EBAY

MATW

SANA

AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday

Vir Biotechnology Inc

Viratech Corp

Neuralbase AI Ltd

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viridien

Pacer Funds Trust BioThreat Strategy ETF

Virtu Financial, Inc. - Class A Common Stock

Virtu Financial Inc

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

Press Releases

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Earnings

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

BRIBY

Ardelyx

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

Chimerix

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Geron

GRAIL

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

LENZ Therapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Zymeworks

Barclays

HC Wainwright & Co.

Needham

Leerink Partners

Morgan Stanley

Comments

Vir Biotechnology

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga